ArticleBrain and behavior2026
Prevalence and Risk Factors for Cerebral Microbleeds in Chinese Patients With Acute Ischemic Stroke.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCerebral microbleeds (CMBs) are recognized as significant markers in acute ischemic stroke (AIS). Although prior studies conducted in southern China have reported CMB prevalence ranging from 27.8% to 56.7% among patients with AIS, data from northern China remain limited, and associated risk factors are not well defined. The aim of this study was to assess the prevalence and determinants of CMBs in a cohort of Chinese patients with AIS.
methodsIn this hospital-based retrospective study, 171 consecutive patients diagnosed with AIS were assessed for the presence, number, and anatomical distribution of CMBs using standardized 3.0 Tesla susceptibility-weighted magnetic resonance imaging protocols. Baseline demographic and clinical variables were collected and analyzed in relation to CMB presence, burden, and location.
resultsThe cohort (mean age 64.8 ± 13.0 years; 73.7% male) demonstrated a CMB prevalence of 49.1%, with variation across TOAST subtypes: large artery atherosclerosis (LAA) (59.4%), small vessel disease (SVD) (47.5%), cardioembolism (21.4%), and other etiologies (25.0%). Multivariate logistic regression identified hypertension (adjusted odds ratio [AOR] = 2.07, 95% confidence interval [CI]: 1.01-4.24) and severe white matter hyperintensity (WMH) (AOR = 4.38, 95% CI: 1.69-11.35) as independent risk factors for the presence of CMBs. Patients with ≥ 3 CMBs had a significantly higher proportion of SVD subtype (58.1% vs. 31.7%, p < 0.01) and lower levels of low-density lipoprotein cholesterol (1.85 vs. 2.38 mmol/L, p < 0.01) when compared with those with 1-2 CMBs. Deep and infratentorial CMBs were associated with a higher frequency of SVD (59.3% and 51.4% vs. 15.0%, p < 0.01) and moderate-to-severe WMH (51.8% and 81.0% vs. 45.0%, p < 0.05) when compared with strictly lobar CMBs.
conclusionApproximately half of the patients with AIS exhibited CMBs, particularly those classified under LAA and SVD subtypes. Hypertension and severe WMH were independently associated with CMB presence. Distinct clinical profiles were observed based on CMB burden and location. Further research is warranted to elucidate underlying mechanisms and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.